It’s always great to start the week off with some good news. Today we learned that the Food and Drug Administration (FDA) has given Asterias Biotherapeutics approval to expand the number and type of people with spinal cord injuries that it treats in their CIRM-funded clinical trial. Up till now, Asterias has been treating people … Continue reading CIRM-funded stem cell clinical trial for spinal cord injury expands patient recruitment
clinical trials
Humacyte Receives Prestigious Technology Pioneer Award for Kidney Failure Treatment
This month, a CIRM-funded company called Humacyte was named one of the World Economic Forum’s 30 Technology Pioneers for 2017. This prestigious award “recognizes early-stage companies from around the world that are involved in the design, development and deployment of new technologies and innovations, and are poised to have a significant impact on business and … Continue reading Humacyte Receives Prestigious Technology Pioneer Award for Kidney Failure Treatment
ViaCyte Advances Cell Replacement Therapy for High Risk Type 1 Diabetes
San Diego regenerative medicine company ViaCyte announced this week that the Food and Drug Administration (FDA) approved their Investigational New Drug (IND) Application for PEC-Direct, a cell-based therapy to treat patients at risk for severe complications caused by type 1 diabetes. In the US, IND approval is the final regulatory step required before a therapy … Continue reading ViaCyte Advances Cell Replacement Therapy for High Risk Type 1 Diabetes
Texas tries to go it alone in offering unproven stem cell therapies to patients
One of the most hotly debated topics in stem cell research is whether patients should be able to have easier access to unproven therapies using their own stem cells, at their own risk, and their own cost. It’s a debate that is dividing patients and physicians, researchers and lawmakers. In California, a bill working its … Continue reading Texas tries to go it alone in offering unproven stem cell therapies to patients
Positively good news from Asterias for CIRM-funded stem cell clinical trial for spinal cord injury
Whenever I give a talk on stem cells one of the questions I invariably get asked is “how do you know the cells are going where you want them to and doing what you want them to?” The answer is pretty simple: you look. That’s what Asterias Biotherapeutics did in their clinical trial to treat … Continue reading Positively good news from Asterias for CIRM-funded stem cell clinical trial for spinal cord injury
Stem cell stories that caught our eye: update on Capricor’s heart attack trial; lithium on the brain; and how stem cells do math
Today our partners Capricor Therapeutics announced that its stem cell therapy for patients who have experienced a large heart attack is unlikely to meet one of its key goals, namely reducing the scar size in the heart 12 months after treatment. The news came after analyzing results from patients at the halfway point of the … Continue reading Stem cell stories that caught our eye: update on Capricor’s heart attack trial; lithium on the brain; and how stem cells do math
A call to put the ‘public’ back in publication, and make stem cell research findings available to everyone
Thomas Gray probably wasn’t thinking about stem cell research when, in 1750 in his poem “Elegy in a Country Churchyard”, he wrote: “Full many a flower is born to blush unseen”. But a new study says that’s precisely what seems to happen to the findings of many stem cell clinical trials. They take place, but … Continue reading A call to put the ‘public’ back in publication, and make stem cell research findings available to everyone
jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
When the US Congress approved, and President Obama signed into law, the 21st Century Cures Act last year there was guarded optimism that this would help create a more efficient and streamlined, but no less safe, approval process for the most promising stem cell therapies. Even so many people took a wait and see approach, … Continue reading jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
jCyte starts second phase of stem cell clinical trial targeting vision loss
Studies show that Americans fear losing their vision more than any other sense, such as hearing or speech, and almost as much as they fear cancer, Alzheimer’s and HIV/AIDS. That’s not too surprising. Our eyes are our connection to the world around us. Sever that connection, and the world is a very different place. For … Continue reading jCyte starts second phase of stem cell clinical trial targeting vision loss
CIRM Alpha Clinics Network charts a new course for delivering stem cell treatments
Sometimes it feels like finding a cure is the easy part; getting it past all the hurdles it must overcome to be able to reach patients is just as big a challenge. Fortunately, a lot of rather brilliant minds are hard at work to find the most effective ways of doing just that. Last week, … Continue reading CIRM Alpha Clinics Network charts a new course for delivering stem cell treatments
The Stem Cellar 